Intravenous Immunoglobulin, Empasiprubart Iv
Guillain-Barré Syndrome (Gbs)
Phase II
Not Yet Recruiting
A Study of Empasiprubart as Add-On Therapy to IVIg in Adult Participants With Guillain-Barré Syndrome
Sep 10, 2026
―
Empasiprubart Iv, Efgartigimod Ph20 Sc Pfs
Gmg, Mg - Myasthenia Gravis, Achr-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis (Mg)
Phase II
Recruiting
ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
Jun 23, 2026
Efgartigimod Iv, Empasiprubart Iv
Generalized Myasthenia Gravis, Myasthenia Gravis, Generalized Myasthenia Gravis (Gmg), Gmg, Mg, Achr-Ab Seropositive Generalized Myasthenia Gravis
Phase II
Recruiting
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
Dec 08, 2025
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Argenx Se (ARGXN) have in its pipeline
ARGXN is currently developing the following drugs: Intravenous Immunoglobulin, Empasiprubart Iv, Argx-121, Empasiprubart Iv, Efgartigimod Ph20 Sc Pfs. These drug candidates are in various stages of clinical development as the company works toward FDA approval.